MiMedx gets access to SaluMedica's Salubria tech for SpineMedica
This article was originally published in Clinica
SpineMedica, a firm that develops treatments for spinal disorders and chronic back pain, has gained access to SaluMedica's Salubria hydrogel technology following a license agreement between the biomaterials specialist and SpineMedica's parent company MiMedx. Under the terms of the deal, MiMedx will have exclusive worldwide rights to use Salubria as a surgical sheet for both internal and external applications. The material, which is designed to have similar properties to human tissue but with increased wear resistance, can be used in surgery for preventing scars and as an anti-adhesive. SpineMedica, based in Atlanta, Georgia, will initially develop the technology for a vessel guard to protect blood vessels during anterior spinal surgeries. Smyrna, Georgia-based SaluMedica will receive upfront 400,000 MiMedx shares for the licence, and an additional 600,000 shares if MiMedx (Tampa, Florida) achieves certain sales milestones by June 2013.